跳至主要内容
临床试验/JPRN-UMIN000012661
JPRN-UMIN000012661已完成未知

An open-label single arm study to evaluate the safety and efficacy of 12-week simeprevir/peginterferon alpha-2a/ribavirin treatment in patients with chronic genotype 1 HCV infection - A study of 12-week simeprevir/peginterferon alpha-2a/ribavirin treatment for chronic genotype 1 HCV infection (LINK study)

Tokai University School of Medicine0 个研究点目标入组 160 人开始时间: 2013年12月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. patients who received treatments containing telaprevir 2. pregnant women 3. patients allergic to ribavirin or IFN 4. patients with uncontrolled heart diseases 5. patients with abnormal hemoglobin 6. patients with chronic renal diseases 7. patients with severe depression or mental illness 8. patients with liver cirrhosis or liver failure 9. patients who cannot discontinue other antiviral or immunomodulating drugs

研究者

相似试验